India, Jan. 30 -- EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last October, expects to report full topline results in the first quarter of 2025.
VERONA is a phase II trial evaluating the company's lead investigational product Duravyu in diabetic macular edema patients previously treated with a standard-of-care FDA-approved anti-VEGF treatment, like intravitreal Aflibercept. Duravyu delivers Vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), formulated in a solid bioerodible insert using EyePoint's proprietary sustained-release Durasert E technology.
Diabetic macular edema (DME) is the primary cause of vision loss among individuals with...